Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeekBreaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek
  • Home
  • Nation
  • Politics
  • Economy
  • Sports
  • Entertainment
  • International
  • Technology
  • Auto News
Reading: Zydus Lifesciences: Broker Recommends Accumulation for Optimal Investment Strategy
Share
Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeekBreaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek
  • Home
  • Nation
  • Politics
  • Economy
  • Sports
  • Entertainment
  • International
  • Technology
  • Auto News
© 2024 All Rights Reserved | Powered by India News Week
Trending Now: Stay updated with the latest breaking news from India and around the world
Broker’s call: Zydus Lifesciences (Accumulate)
Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek > Economy > Zydus Lifesciences: Broker Recommends Accumulation for Optimal Investment Strategy
Economy

Zydus Lifesciences: Broker Recommends Accumulation for Optimal Investment Strategy

Indianewsweek By Indianewsweek May 21, 2026 2 Min Read
Share
SHARE

Target Price: ₹1,080
Current Market Price: ₹1,040.95

Zydus Lifesciences (ZYDUSLIF) reported a Q4 EBITDA that exceeded expectations, driven by increased revenues in key markets. The company appears to have a stable base business, albeit with slight erosion. Year-on-year growth was supported by higher sales in the U.S., along with the integration of MedTech and Comfort Click performance.

Domestic formulations recorded a growth of approximately 14% year-on-year, while the consumer segment saw a significant increase of 61% year-on-year, boosted by a complete quarter of Comfort Click’s performance.

The company is actively developing a robust pipeline of complex products, including injectables, 505(b)(2) applications, transdermals, new chemical entities, biosimilars, and vaccines, which are anticipated to launch over the next 2 to 3 years.

U.S. sales are projected to remain relatively flat for FY26-28E due to erosion in some key product lines, leading to an expected flat EPS CAGR when adjusted for foreign exchange over the same period.

Management has indicated plans for the launch of 2-3 high-value products in FY27E and FY28E, noting that timely launches will be vital for maintaining momentum in U.S. sales. U.S. sales reached $323 million, a 2.5% increase quarter-on-quarter, compared to the estimated $300 million. Emerging markets experienced a robust growth of 51% year-on-year, amounting to ₹730 crore. API revenues remained stagnant year-on-year, while the MedTech division reported revenues of ₹330 crore, a 10% increase quarter-on-quarter.

The FY27/28E EPS estimates are largely unchanged. Consequently, the company maintains an ‘Accumulate’ rating with a target price of ₹1,080, based on a valuation of 23 times the FY28E EPS.

Published on May 20, 2026

TAGGED:Economy NewsNews
Share This Article
Twitter Copy Link
Previous Article Hotels, guesthouses get industry status in Ladakh Ladakh’s Hotels and Guesthouses Achieve Industry Status, Boosting Tourism Potential
Next Article Stock Market Live May 20: Stock to buy today: Manappuram Finance Sensex Gains 117 Points as Stock Markets Rebound on Late-Day Buying Surge
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

NHRC Issues Notice to MP Government Over Children’s Risky Commute to School

November 23, 2026
SEBI starts work on network to train independent directors

SEBI Launches Initiative to Train Independent Directors with New Network Program

November 22, 2026
IPO Street set for year-end revival; 29 firms eye ₹42,000 crore as sentiment improves

IPO Market Poised for Year-End Upsurge with 29 Firms Targeting ₹42,000 Crore as Optimism Grows

November 22, 2026
Photos: People rally across France over living costs, public services

Protests Erupt Across France as Citizens Demand Action on Rising Living Costs

November 22, 2026
Govt revises policy for extending pre-NELP oil, gas contracts; raises government profit share

Government Updates Pre-NELP Oil and Gas Contracts Policy, Increasing Profit Share for Treasury

November 22, 2026
US Market Outlook: Indices plunge deeply

US Stock Market Forecast: Indices Experience Significant Decline

November 22, 2026

You Might Also Like

Soyabean, sunflower oils push India’s edible oil imports up by 13%
Economy

India’s Edible Oil Imports Surge by 13% fueled by Soyabean and Sunflower Oils

2 Min Read
Denta Water IPO enters day 2 with 17x subscription
Economy

Denta Water IPO Day 2: Surpasses Expectations with 17x Subscription

2 Min Read
Top gainers, losers on NSE, BSE today 24th Oct: Sensex, Nifty pare early gains on profit booking, HUL, Laurus Labs, Colgate shares decline, Hindalco lead gainers
Economy

Market Update: Hindalco Soars as HUL and Colgate Dip on NSE, BSE

3 Min Read
Cricketers keeping wickets for startup founders
Economy

Cricketers Turn Wicketkeepers to Support Startup Founders in Innovative Business Partnership

6 Min Read

About IndiaNewsWeek

IndiaNewsWeek is your trusted source for breaking news, in-depth analysis, and comprehensive coverage of India and the world. We deliver accurate, timely reporting across politics, economy, sports, entertainment, and technology.

contact@indianewsweek.com

Quick Links

  • Nation
  • Politics
  • Economy
  • International
  • Sports
  • Entertainment

More Sections

  • Technology
  • Auto News
  • Education
  • About Us
  • Contact
  • Privacy Policy

Stay Connected

Follow us on social media for the latest updates and breaking news.

Facebook
X (Twitter)
YouTube
Follow US
© 2026 IndiaNewsWeek. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?